Lecanemab Data On Benefit In Alzheimer’s Might Satisfy FDA – But What About Medicare?

Centers for Medicare and Medicaid Services’ standard for determining whether drugs produce a clinically meaningful improvement in cognition that would allow for broader Medicare coverage is unclear. But Eisai/Biogen’s lecanemab is likely to serve as a first test.